{"product_id":"bcma-cd20-firefly-luciferase-cho-cell-line-bhc18200093","title":"BCMA \/ CD20 \/ Firefly Luciferase CHO Cell Line","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table tr:nth-child(even) th{background:#dce8fb}\n.bhp-desc .bhp-spec-table tr:nth-child(even) td{background:#f0f6ff}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600;margin-bottom:10px}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-license-box{background:#f5f5f5;border:1px solid #ddd;border-radius:4px;padding:12px 16px;font-size:14px;color:#444;margin:10px 0 14px}\n.bhp-desc .bhp-regulatory-row{display:flex;gap:16px;flex-wrap:wrap;margin:6px 0 10px}\n.bhp-desc .bhp-reg-item{background:#f0f6ff;border:1px solid #ccd9f0;border-radius:4px;padding:6px 12px;font-size:14px}\n.bhp-desc .bhp-reg-item strong{color:#003366;display:block;font-size:12px;text-transform:uppercase;letter-spacing:.5px}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n\u003ch2\u003eScientific Background\u003c\/h2\u003e\n\u003cp\u003eB-Cell Maturation Antigen (BCMA), also known as CD269, is a cell surface receptor of the TNF receptor superfamily that recognizes B-Cell Activating Factor (BAFF). BCMA is preferentially expressed on mature B-lymphocytes and Multiple Myeloma (MM) cells. BCMA is a highly attractive target antigen for immunotherapy, not only because of its restricted expression in nonmalignant tissue, but also due to its almost universal expression on MM cells. Pre-clinical studies using CAR (Chimeric Antigen Receptor) T-cells targeting BCMA have demonstrated anti-MM activity, and in 2017, the FDA granted BCMA CAR T-Cell immunotherapy the breakthrough designation in treating Multiple Myeloma. CD20 (MS4A1) is a glycosylated phosphoprotein expressed on the cell surface of B cells. Although the functional significance of CD20 is not clear, and CD20 has no known ligands, CD20 has been shown to regulate intracellular calcium levels. CD20 is a highly attractive target antigen for immunotherapy because it is expressed in more than 90% of patients with B-cell lymphoma. First approved in 1997, Rituximab (Rituxan) is a chimeric monoclonal antibody targeting CD20 and has been classified by the World Health Organization as an \"Essential Medicine\". Since then, additional monoclonal antibodies against CD20 have been approved or are being tested in clinical trials for the treatment of multiple sclerosis (MS), chronic lymphocytic leukemia (CLL), follicular lymphoma, diffuse large B cell lymphoma (DLBCL), rheumatoid arthritis, non-Hodgkin's lymphoma, systemic lupus erythematosus, and myalgic encephalomyelitis (chronic fatigue syndrome). Additionally, more recently, anti-CD20-CD19 bispecific CAR-T cells have been developed to address concerns over potential relapse.\u003c\/p\u003e\n\u003ch2\u003eProduct Description\u003c\/h2\u003e\n\u003cspan class=\"bhp-cat-pill\"\u003eCAR-T\u003c\/span\u003e\n\u003cp\u003eClonal stable CHO cell line constitutively expressing full length human BCMA protein (also known as CD269 or TNFRSF17, Genbank accession #NM_001192) and human CD20 protein (also known as MS4A1 or FMC7, Genbank accession #NM_021950). This cell line was derived from our CHO-K1 Luciferase cells (BPS Bioscience, #79725), therefore it also constitutively expresses the firefly luciferase reporter. Surface expressions of BCMA and CD20 were confirmed by flow cytometry.\u003c\/p\u003e\n\u003ch2\u003eProduct Specifications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eHost Cell Line\u003c\/th\u003e\n\u003ctd\u003eCHO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eHost Species\u003c\/th\u003e\n\u003ctd\u003eHamster\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eTransfection Method\u003c\/th\u003e\n\u003ctd\u003eLipofectamine 2000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eSupplied As\u003c\/th\u003e\n\u003ctd\u003e2 vials of frozen cells. 2 x 10\u003csup\u003e6\u003c\/sup\u003e cells in 1 ml of 10% DMSO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eHarmonized Tariff Code\u003c\/th\u003e\n\u003ctd\u003e3002-5900\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eQuality Control \u0026amp; Validation\u003c\/h2\u003e\n\u003cspan class=\"bhp-qc-badge\"\u003e✓ Mycoplasma-Tested\u003c\/span\u003e\n\u003cp\u003eThe cell line has been screened using the MycoAlert™ Mycoplasma Detection kit (Lonza, #LT07-218) to confirm the absence of Mycoplasma species.\u003c\/p\u003e\n\u003ch2\u003eUsage Notes\u003c\/h2\u003e\n\u003cp\u003eSee assay protocol for detailed instructions.\u003c\/p\u003e\n\u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n\u003cdiv class=\"bhp-warning-box\"\u003e\n\u003cp style=\"margin:0 0 4px\"\u003e⚠ Avoid freeze\/thaw cycles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003ch2\u003eRegulatory Information\u003c\/h2\u003e\n\u003cdiv class=\"bhp-regulatory-row\"\u003e\n\u003cdiv class=\"bhp-reg-item\"\u003e\n\u003cstrong\u003eLicense Required\u003c\/strong\u003eYes\u003c\/div\u003e\n\u003cdiv class=\"bhp-reg-item\"\u003e\n\u003cstrong\u003eLiving Modified Organism\u003c\/strong\u003eYes\u003c\/div\u003e\n\u003c\/div\u003e\n\u003ch2\u003eLicense Disclosure\u003c\/h2\u003e\n\u003cdiv class=\"bhp-license-box\"\u003eVisit bpsbioscience.com\/license for the label license and other key information about this product. Troubleshooting Guide: Visit bpsbioscience.com\/cell-line-faq for detailed troubleshooting instructions. For all further questions, please email support@bpsbioscience.com.\u003c\/div\u003e\n\u003ch2\u003eRelated Products\u003c\/h2\u003e\n\u003cp\u003eRelated Products: Cat. #60690, 60186, 78041, 78186\u003c\/p\u003e\n\u003cp\u003eRequired Accessories: Cat. #60186,78041,79796\u003c\/p\u003e\n\u003c\/div\u003e","brand":"BPS Bioscience","offers":[{"title":"2 Vials","offer_id":53322315825517,"sku":"78185","price":9975.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/78185_fig_1.png?v=1778636456","url":"https:\/\/www.ebiohippo.com\/products\/bcma-cd20-firefly-luciferase-cho-cell-line-bhc18200093","provider":"BioHippo","version":"1.0","type":"link"}